Carboplatin
- Generic Name
- Carboplatin
- Brand Names
- Paraplatin
- Drug Type
- Small Molecule
- Chemical Formula
- C6H12N2O4Pt
- CAS Number
- 41575-94-4
- Unique Ingredient Identifier
- BG3F62OND5
Overview
Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting. Carboplatin was granted FDA approval on 3 March 1989.
Background
Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting. Carboplatin was granted FDA approval on 3 March 1989.
Indication
Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.
Associated Conditions
- Advanced Cervical Cancer
- Advanced Endometrial Cancer
- Advanced Esophageal Cancers
- Advanced Head and Neck Cancer
- Advanced Melanoma
- Advanced Non-Small Cell Lung Cancer (NSCLC)
- Advanced Ovarian Carcinoma
- Advanced Sarcoma
- Malignant Pleural Mesothelioma (MPM)
- Merkel Cell Carcinoma
- Metastatic Breast Cancer
- Refractory Hodgkin Lymphoma
- Retinoblastoma
- Thymoma
- Advanced Bladder cancer
- Advanced Small cell lung cancer
- Advanced Testicular cancer
- Advanced Thymoma
- Refractory Non-Hodgkin's lymphoma
Clinical Trials
FDA Approved Products
Singapore Approved Products
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.